Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remifentanil dose-finding for suppression of hemodynamic response during SLIPA insertion
ACTRN12613000086763Phase 4Completed
- Sponsor
- Chung-Ang University
- Start
- Jan 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of remifentanil (5 arms), sponsored by Chung-Ang University. Primary endpoints: Systolic blood pressure, Mean arterial pressure and 1 more. Started Jan 2011; status: completed.
02
Drugs
remifentanil
Beyond the preview
Go deeper on ACTRN12613000086763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000086763.